Description
Udaforce (Udenafil) 200 mg
Udaforce is identified here as a product containing udenafil. Udenafil is a phosphodiesterase type 5 (PDE5) inhibitor used in the treatment of erectile dysfunction. Published clinical studies and reviews describe it as an oral medicine that improves erectile function in adult men with erectile dysfunction.
Active Ingredient and Medicine Class
Active ingredient: udenafil.
Medicine class: PDE5 inhibitor. This class is related to other medicines used for erectile dysfunction, such as sildenafil and tadalafil. Udenafil has been studied as a selective PDE5 inhibitor.
Established Medical Uses
The established use supported by the sources reviewed is the treatment of erectile dysfunction. Clinical trials and meta-analysis data show improved erectile function scores and higher rates of successful intercourse-related outcomes compared with placebo. Some studies also evaluated men with hypertension or diabetes, where benefit was still observed.
How It Works
Udenafil inhibits PDE5, an enzyme involved in regulating blood flow in penile tissue. By blocking PDE5, it helps preserve the smooth-muscle relaxation and increased blood flow needed for an erection in response to sexual stimulation.
Important Safety Information
Like other PDE5 inhibitors, udenafil is contraindicated with organic nitrates because the combination can cause a dangerous fall in blood pressure. Reviews also note caution with alpha-blockers and other medicines that lower blood pressure. Cardiovascular status should be considered before use in people with heart disease.
Clinically significant interactions can also occur with medicines that strongly affect PDE5 inhibitor exposure, although specific product-label details for this brand could not be verified from the sources available here.
Possible Side Effects
Commonly reported adverse effects in clinical studies include headache, flushing, nausea, rhinorrhea, and conjunctival hyperemia. Most reported events were mild to moderate. Serious adverse events were not reported in the studies reviewed, but all PDE5 inhibitors can cause clinically important blood-pressure-related reactions when combined with nitrates.
Scientific Evidence
Randomized controlled trials and a meta-analysis found that udenafil improved erectile function compared with placebo, with results consistent across different study populations. The evidence base is smaller than for some older PDE5 inhibitors, but the available human studies support efficacy and general tolerability in erectile dysfunction.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, prescribing information, or assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA), Public summary of opinion on orphan designation: udenafil for treatment of functional single ventricle congenital heart disease.
- Hui Ding et al., “Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials,” Urology, 2012. PubMed.
